News Sentiment

ENTX sentiment intelligence

Entera Bio Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.66 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-0.3% over one week, +34.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -0.3% Price digesting
Trend fit Trend inactive 34.6% over four weeks
Fair value 1.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 30
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 7
Market source 6
GlobeNewswire 5
TradingKey 4
simplywall.st 3
Investing.com 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 16
Analyst action 4
Deals and strategy 1
Guidance 1
Regulatory and legal 1
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
Stock Titan Direct company coverage

Daily oral tablet EB613 shows comparable results to Forteo

Entera Bio presented Phase 1 data at ENDO 2026 for its single-tablet oral EB613, showing comparable pharmacokinetic (PK) and pharmacodynamic (PD) profiles, calcemic effects, and safety to multi-tablet EB613 and injectable Forteo. This data supports advancing the single-tablet for

Tone
Positive 65/100
Event
Earnings
Published
15 Jun 2026 12:40
Source
Stock Titan